Cited by — The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts.
No admitted local citation edges point to this work yet.
